Patients of African ancestry less likely to qualify for colorectal cancer immunotherapy

Individuals of African ancestry treated for colorectal cancer had fewer actionable genetic alterations than those of European ancestry, making them less likely to be eligible for immunotherapy, study results showed.The findings, presented at American Association for Cancer Research Annual Meeting, revealed that patients of European ancestry who had microsatellite-stable disease and low tumor mutational burden had double the rate of clinically actionable alterations compared with those of African ancestry. In addition, researchers reported markedly shorter median OS among individuals ofRead More